Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Alnylam Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 525 | 5 | 569 | +49 |
| Shares | 119.9M | 9.63M | 123.8M | +13.6M (+12.3%) |
| Value | $29.1B | $2.34B | $34.1B | +$7.26B (+27.1%) |
5 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (107)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Showing the largest 100 of 107 by value.
Sold out (58)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
Not filed for Q3 2024 yet (5)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 9,547,663 | $2.32B |
| Susquehanna Fundamental Investments, LLC | 56,585 | $13.8M |
| Fjarde AP-fonden (The Fourth Swedish National Pensionfund) | 28,415 | $6.91M |
| Benjamin F. Edwards & Company, Inc. | 356 | $87.0K |
| JJJ Advisors Inc. | 8 | $1.94K |